Logo of thoraxThoraxVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Thorax. 2005 Jan; 60(1): 32–38.
PMCID: PMC1747159

Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status


Background: Skeletal muscle weakness is assumed to be present in patients with sarcoidosis but has never been reported in a consecutive group of patients. Moreover, its relationship with previously observed exercise intolerance and reduced health status has never been studied in these patients.

Methods: Pulmonary function, skeletal and respiratory muscle forces, peak and functional exercise capacity, health status, and the circulating levels of inflammatory and anabolic markers were determined in 25 patients with sarcoidosis who complained of fatigue (15 men) and in 21 healthy subjects (13 men).

Results: Patients with sarcoidosis had lower respiratory and skeletal muscle forces, reduced exercise capacity and health status, higher anxiety and depression scores, and higher circulating levels of tumour necrosis factor-α than healthy subjects (all p⩽0.01). Its soluble receptor p75 tended to be higher (p = 0.04). Circulating levels of interleukin (IL)-6, IL-8, insulin-like growth factor I and its binding protein 3 were not significantly different between the two groups. Skeletal muscle weakness was related to exercise intolerance, depression, and reduced health status in patients with sarcoidosis, irrespective of age, sex, body weight and height (p⩽0.05). Quadriceps peak torque was inversely related to fatigue but not to the circulating levels of inflammatory or anabolic markers. The mean daily dose of corticosteroids received in the 6 month period before testing was related to quadriceps peak torque only in patients who received oral corticosteroids.

Conclusion: Skeletal muscle weakness occurs in patients with sarcoidosis who complain of fatigue and is associated with reduced health status and exercise intolerance.

Full Text

The Full Text of this article is available as a PDF (142K).

Supplementary Material

[Web-only Appendix and Figures]

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Chang B, Steimel J, Moller DR, Baughman RP, Judson MA, Yeager H, Jr, Teirstein AS, Rossman MD, Rand CS. Depression in sarcoidosis. Am J Respir Crit Care Med. 2001 Feb;163(2):329–334. [PubMed]
  • Drent M, Wirnsberger RM, Breteler MH, Kock LM, de Vries J, Wouters EF. Quality of life and depressive symptoms in patients suffering from sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1998 Mar;15(1):59–66. [PubMed]
  • Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health-related quality of life in patients with interstitial lung disease. Chest. 1999 Nov;116(5):1175–1182. [PubMed]
  • Wirnsberger RM, Drent M, Hekelaar N, Breteler MH, Drent S, Wouters EF, Dekhuijzen PN. Relationship between respiratory muscle function and quality of life in sarcoidosis. Eur Respir J. 1997 Jul;10(7):1450–1455. [PubMed]
  • Arcasoy SM, Christie JD, Pochettino A, Rosengard BR, Blumenthal NP, Bavaria JE, Kotloff RM. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest. 2001 Sep;120(3):873–880. [PubMed]
  • Delobbe Alain, Perrault Hélène, Maitre Jocelyne, Robin Sophie, Hossein-Foucher Claude, Wallaert Benoit, Aguilaniu Bernard. Impaired exercise response in sarcoid patients with normal pulmonary functio. Sarcoidosis Vasc Diffuse Lung Dis. 2002 Jun;19(2):148–153. [PubMed]
  • Medinger AE, Khouri S, Rohatgi PK. Sarcoidosis: the value of exercise testing. Chest. 2001 Jul;120(1):93–101. [PubMed]
  • Miller A, Brown LK, Sloane MF, Bhuptani A, Teirstein AS. Cardiorespiratory responses to incremental exercise in sarcoidosis patients with normal spirometry. Chest. 1995 Feb;107(2):323–329. [PubMed]
  • Sietsema KE, Kraft M, Ginzton L, Sharma OP. Abnormal oxygen uptake responses to exercise in patients with mild pulmonary sarcoidosis. Chest. 1992 Sep;102(3):838–845. [PubMed]
  • Anker SD, Swan JW, Volterrani M, Chua TP, Clark AL, Poole-Wilson PA, Coats AJ. The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J. 1997 Feb;18(2):259–269. [PubMed]
  • Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med. 1996 Mar;153(3):976–980. [PubMed]
  • Paramothayan Shanthi, Jones Paul W. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA. 2002 Mar 13;287(10):1301–1307. [PubMed]
  • Silverstein A, Siltzbach LE. Muscle involvement in sarcoidosis. Asymptomatic, myositis, and myopathy. Arch Neurol. 1969 Sep;21(3):235–241. [PubMed]
  • Drent M, Wirnsberger RM, de Vries J, van Dieijen-Visser MP, Wouters EF, Schols AM. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J. 1999 Apr;13(4):718–722. [PubMed]
  • Ziegenhagen MW, Müller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med. 2003 Jan;253(1):18–30. [PubMed]
  • Barry Sinead C, Gallagher Charles G. Corticosteroids and skeletal muscle function in cystic fibrosis. J Appl Physiol (1985) 2003 Oct;95(4):1379–1384. [PubMed]
  • Bilici M, Koroglu MA, Cakirbay H, Guler M, Tosun M, Aydin T, Tan U. Isokinetic muscle performance in major depressive disorder: alterations by antidepressant therapy. Int J Neurosci. 2001 Aug;109(3-4):149–164. [PubMed]
  • Cicoira M, Bolger AP, Doehner W, Rauchhaus M, Davos C, Sharma R, Al-Nasser FO, Coats AJ, Anker SD. High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. Cytokine. 2001 Jul 21;15(2):80–86. [PubMed]
  • De Becker P, Roeykens J, Reynders M, McGregor N, De Meirleir K. Exercise capacity in chronic fatigue syndrome. Arch Intern Med. 2000 Nov 27;160(21):3270–3277. [PubMed]
  • Decramer M, de Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1958–1964. [PubMed]
  • Fulcher KY, White PD. Strength and physiological response to exercise in patients with chronic fatigue syndrome. J Neurol Neurosurg Psychiatry. 2000 Sep;69(3):302–307. [PMC free article] [PubMed]
  • Fernández-Celemín Laura, Pasko Nevi, Blomart Valerie, Thissen Jean-Paul. Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab. 2002 Dec;283(6):E1279–E1290. [PubMed]
  • Hambrecht Rainer, Schulze Paul Christian, Gielen Stephan, Linke Axel, Möbius-Winkler Sven, Yu Jiangtao, Kratzsch J J ürgen, Baldauf Gerhard, Busse Martin W, Schubert Andreas, et al. Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. J Am Coll Cardiol. 2002 Apr 3;39(7):1175–1181. [PubMed]
  • Spruit MA, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G, Bogaerts P, Bouillon R, Decramer M. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax. 2003 Sep;58(9):752–756. [PMC free article] [PubMed]
  • Ziegenhagen MW, Schrum S, Zissel G, Zipfel PF, Schlaak M, Müller-Quernheim J. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J Investig Med. 1998 Jun;46(5):223–231. [PubMed]
  • SCADDING JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J. 1961 Nov 4;2(5261):1165–1172. [PMC free article] [PubMed]
  • Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Veldhuis JD. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. J Clin Endocrinol Metab. 2000 Jan;85(1):183–192. [PubMed]
  • Guyatt GH, Pugsley SO, Sullivan MJ, Thompson PJ, Berman L, Jones NL, Fallen EL, Taylor DW. Effect of encouragement on walking test performance. Thorax. 1984 Nov;39(11):818–822. [PMC free article] [PubMed]
  • Jones NL, Makrides L, Hitchcock C, Chypchar T, McCartney N. Normal standards for an incremental progressive cycle ergometer test. Am Rev Respir Dis. 1985 May;131(5):700–708. [PubMed]
  • Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997 Nov;35(11):1095–1108. [PubMed]
  • Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361–370. [PubMed]
  • Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987 Oct;42(10):773–778. [PMC free article] [PubMed]
  • Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed) 1986 Mar 15;292(6522):746–750. [PMC free article] [PubMed]
  • Altman DG, Gore SM, Gardner MJ, Pocock SJ. Statistical guidelines for contributors to medical journals. Br Med J (Clin Res Ed) 1983 May 7;286(6376):1489–1493. [PMC free article] [PubMed]
  • Hearth-Holmes M, Campbell GD., Jr Muscle weakness, fatigue, and joint pain in a 52-year-old woman. Chest. 1995 Aug;108(2):563–564. [PubMed]
  • Jamal MM, Cilursu AM, Hoffman EL. Sarcoidosis presenting as acute myositis. Report and review of the literature. J Rheumatol. 1988 Dec;15(12):1868–1871. [PubMed]
  • Mozaffar T, Lopate G, Pestronk A. Clinical correlates of granulomas in muscle. J Neurol. 1998 Aug;245(8):519–524. [PubMed]
  • Chaudhuri Abhijit, Behan Peter O. Fatigue in neurological disorders. Lancet. 2004 Mar 20;363(9413):978–988. [PubMed]
  • El Azab SR, Rosseel PMJ, de Lange JJ, Groeneveld ABJ, van Strik R, van Wijk EM, Scheffer GJ. Dexamethasone decreases the pro- to anti-inflammatory cytokine ratio during cardiac surgery. Br J Anaesth. 2002 Apr;88(4):496–501. [PubMed]
  • Bourjeily-Habr G, Rochester CL, Palermo F, Snyder P, Mohsenin V. Randomised controlled trial of transcutaneous electrical muscle stimulation of the lower extremities in patients with chronic obstructive pulmonary disease. Thorax. 2002 Dec;57(12):1045–1049. [PMC free article] [PubMed]
  • Neder JA, Sword D, Ward SA, Mackay E, Cochrane LM, Clark CJ. Home based neuromuscular electrical stimulation as a new rehabilitative strategy for severely disabled patients with chronic obstructive pulmonary disease (COPD). Thorax. 2002 Apr;57(4):333–337. [PMC free article] [PubMed]
  • Simpson K, Killian K, McCartney N, Stubbing DG, Jones NL. Randomised controlled trial of weightlifting exercise in patients with chronic airflow limitation. Thorax. 1992 Feb;47(2):70–75. [PMC free article] [PubMed]
  • Spruit MA, Gosselink R, Troosters T, De Paepe K, Decramer M. Resistance versus endurance training in patients with COPD and peripheral muscle weakness. Eur Respir J. 2002 Jun;19(6):1072–1078. [PubMed]
  • Emery CF, Schein RL, Hauck ER, MacIntyre NR. Psychological and cognitive outcomes of a randomized trial of exercise among patients with chronic obstructive pulmonary disease. Health Psychol. 1998 May;17(3):232–240. [PubMed]
  • Adamopoulos Stamatis, Parissis John, Karatzas Dimitrios, Kroupis Christos, Georgiadis Michael, Karavolias George, Paraskevaidis John, Koniavitou Katerina, Coats Andrew J S, Kremastinos Dimitrios Th. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. J Am Coll Cardiol. 2002 Feb 20;39(4):653–663. [PubMed]
  • Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol. 1996 Nov;49(11):1215–1219. [PubMed]
  • Grimes David A, Schulz Kenneth F. An overview of clinical research: the lay of the land. Lancet. 2002 Jan 5;359(9300):57–61. [PubMed]
  • Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H, Jr, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1885–1889. [PubMed]
  • Sharma SK, Mohan A, Guleria JS. Clinical characteristics, pulmonary function abnormalities and outcome of prednisolone treatment in 106 patients with sarcoidosis. J Assoc Physicians India. 2001 Jul;49:697–704. [PubMed]
  • Cox Christopher E, Donohue James F, Brown Cynthia D, Kataria Yash P, Judson Marc A. The Sarcoidosis Health Questionnaire: a new measure of health-related quality of life. Am J Respir Crit Care Med. 2003 Aug 1;168(3):323–329. [PubMed]
  • Lareau SC, Breslin EH, Meek PM. Functional status instruments: outcome measure in the evaluation of patients with chronic obstructive pulmonary disease. Heart Lung. 1996 May-Jun;25(3):212–224. [PubMed]
  • DeRemee RA. Dysphoria and sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1998 Mar;15(1):21–21. [PubMed]
  • Drent M. Sarcoidosis: benefits of a multidisciplinary approach. Eur J Intern Med. 2003 Jul;14(4):217–220. [PubMed]

Articles from Thorax are provided here courtesy of BMJ Group


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...